Unknown

Dataset Information

0

Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies.

ABSTRACT:

SUBMITTER: Cheng L 

PROVIDER: S-EPMC8608826 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera.
| S-EPMC8541826 | biostudies-literature
Unknown Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.
| S-EPMC8058618 | biostudies-literature
Unknown SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies.
| S-EPMC7885928 | biostudies-literature
Unknown Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians.
| S-EPMC8450274 | biostudies-literature
Unknown High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals.
| S-EPMC8687746 | biostudies-literature
Unknown B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies.
| S-EPMC8406170 | biostudies-literature
Unknown mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
| S-EPMC8503938 | biostudies-literature
Unknown SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies.
| S-EPMC7899479 | biostudies-literature
Unknown Emerging SARS-CoV-2 B.1.621/Mu variant is prominently resistant to inactivated vaccine-elicited antibodies.
| S-EPMC8645883 | biostudies-literature
Unknown Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
| S-EPMC173409 | biostudies-other